+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cystic Fibrosis Market - Global Forecast 2026-2032- Product Image
Cystic Fibrosis Market - Global Forecast 2026-2032- Product Image
Sale

Cystic Fibrosis Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6084162
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cystic Fibrosis Market is projected to reach USD 7.71 Billion in 2026. It is expected to continue growing at a CAGR of 9.79%, reaching USD 13.61 Billion by 2032.

Cystic fibrosis is a life-limiting, autosomal recessive disease caused by pathogenic variants in the CFTR gene, leading to impaired chloride and bicarbonate transport, thick mucus, recurrent respiratory infections, pancreatic insufficiency, and multisystem complications. The cystic fibrosis market is shaped by a high clinical burden, lifelong treatment needs, and a rapidly evolving standard of care centered on CFTR modulators, airway clearance, anti-infectives, mucolytics, nutritional support, and multidisciplinary disease management.

Verified registry and foundation data indicate that more than 105,000 people are living with diagnosed cystic fibrosis across 90-plus countries, with the highest documented prevalence in North America and Europe. Earlier diagnosis through newborn screening, longer survival, and broader access to precision therapies are expanding the treated population, while health systems continue to address gaps in equitable access, genotype coverage, infection control, and long-term outcomes.

Transformative Shifts in the Cystic Fibrosis Landscape

The cystic fibrosis landscape has shifted from symptom management toward genotype-directed disease modification. CFTR modulators, particularly highly effective triple-combination therapy for eligible patients, have changed expectations for lung function, pulmonary exacerbation reduction, nutritional status, and quality of life. This transition is reshaping demand across pharmaceuticals, diagnostics, specialty pharmacy, companion testing, and longitudinal monitoring.

At the same time, unmet needs remain substantial for people with rare or nonresponsive CFTR variants, advanced lung disease, chronic Pseudomonas aeruginosa or Burkholderia cepacia complex infection, liver disease, cystic fibrosis-related diabetes, infertility, and treatment-related access barriers. The next competitive phase is expected to emphasize mutation-agnostic strategies, mRNA and gene editing platforms, inhaled delivery systems, antimicrobial resistance management, and real-world evidence demonstrating durable clinical value.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler across cystic fibrosis research and care. AI-supported image analysis can quantify structural lung disease from CT and MRI, while machine learning models are being evaluated to anticipate pulmonary exacerbations using spirometry, symptoms, microbiology, wearable data, and electronic health records. These tools can help clinicians identify deterioration earlier and personalize follow-up intensity.

AI is also accelerating drug discovery by supporting CFTR variant interpretation, protein-structure modeling, candidate screening, clinical trial enrichment, and pharmacovigilance. The cumulative impact is strongest when AI is paired with validated registries, standardized endpoints, and privacy-preserving data governance. Industry leaders should view AI as a decision-support layer rather than a replacement for specialist-led cystic fibrosis care.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

North America remains the most mature cystic fibrosis market, led by the United States and Canada, where newborn screening, accredited care centers, registries, and access to advanced CFTR modulators support high treatment penetration. Europe is similarly advanced, with strong specialist networks, national registries, and reimbursement pathways, although country-level access timelines differ across the European Union and non-EU markets.

Asia-Pacific is expanding through improved diagnosis, rising specialty-care capacity, and increasing awareness in China, India, Japan, South Korea, and Australia, but underdiagnosis and genotype diversity remain important constraints. Latin America, the Middle East, and Africa show growing clinical recognition and newborn screening adoption in select countries, yet access to modulators, sweat testing, genetic testing, and infection-control infrastructure remains uneven. These regional differences make market access, affordability, local evidence generation, and clinician training essential for sustainable growth.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, cystic fibrosis is historically underdiagnosed because the disease is less common than in populations of European ancestry and diagnostic infrastructure varies widely; however, expanding genomic medicine, pediatric pulmonology capacity, and referral networks are improving case identification. GCC countries are investing in specialized healthcare infrastructure, genetic testing, premarital and carrier screening programs, and rare disease pathways, creating opportunities for earlier diagnosis and precision treatment access.

The European Union benefits from coordinated rare disease policy, cross-border research networks, newborn screening expansion, and established cystic fibrosis registries, while BRICS markets present a mixed profile: China, India, and Brazil offer large population bases and improving specialty access, whereas affordability and diagnostic coverage remain key barriers. G7 markets lead in innovation, reimbursement sophistication, clinical trial infrastructure, and real-world evidence generation. NATO member countries overlap heavily with North American and European advanced-care markets, supporting strong clinical trial capacity, standardized treatment protocols, and high adoption of specialist-led care models.

Key Country Insights Across Major Cystic Fibrosis Markets

The United States is the global commercial anchor for cystic fibrosis innovation, supported by a large diagnosed population, advanced care-center infrastructure, newborn screening, and broad use of CFTR modulators among eligible patients. Canada shows similar clinical sophistication with centralized assessment, provincial reimbursement processes, and strong specialist care. Mexico and Brazil are strengthening diagnosis, newborn screening, and specialist access, but affordability and regional disparities continue to influence treatment uptake.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain robust cystic fibrosis care models, registries, newborn screening programs, and reimbursement systems, while Russia faces more variable access across regions. China and India are increasingly important due to expanding genetic testing, pediatric respiratory care, and rising rare disease awareness, though underdiagnosis remains significant. Japan, Australia, and South Korea combine high-quality healthcare systems with growing precision medicine adoption, supporting opportunities in diagnostics, specialty therapeutics, adherence support, and long-term outcome monitoring.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize broad genotype coverage, durable real-world outcomes, and access strategies that reflect local payer expectations. Developers of CFTR modulators, anti-infectives, mucolytics, gene-based therapies, or digital monitoring tools should invest early in biomarker validation, registry partnerships, patient-reported outcomes, and evidence packages that demonstrate reduced exacerbations, hospitalization avoidance, improved lung function, and better long-term quality of life.

Commercial and medical teams should also strengthen collaborations with cystic fibrosis centers, patient organizations, diagnostic laboratories, and public health agencies. Practical priorities include expanding newborn screening, improving sweat chloride and genetic testing access, supporting antimicrobial stewardship, reducing treatment burden, improving adherence support, and designing equitable access models for low- and middle-income markets.

Research Methodology

Research methodology is built from verified secondary research, including peer-reviewed cystic fibrosis literature, public health guidance, regulatory information, clinical trial databases, newborn screening references, patient registry insights, and publicly available information from recognized cystic fibrosis foundations and specialist organizations. Market interpretation emphasizes evidence that is clinically validated, reproducible, and relevant to industry decision-making.

The methodology combines disease epidemiology review, therapy landscape assessment, regional access evaluation, and qualitative analysis of innovation trends. Insights are triangulated across clinical standards, regulatory approvals, reimbursement patterns, registry findings, and real-world care infrastructure to provide an objective view of the cystic fibrosis market without relying on unsupported assumptions, market estimation, or forecasting.

Conclusion

The cystic fibrosis market is entering a new phase defined by precision medicine, earlier diagnosis, long-term disease modification, and rising expectations for equitable access. CFTR modulators have transformed outcomes for many eligible patients, but significant unmet needs persist for rare variants, advanced complications, chronic infection, and regions with limited diagnostic or reimbursement capacity.

Future leadership will depend on therapies and services that expand eligibility, reduce treatment burden, and prove durable value in real-world settings. Organizations that combine scientific innovation with strong access planning, registry-based evidence, and patient-centered care models will be best positioned in the global cystic fibrosis ecosystem.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cystic Fibrosis Market, by Treatment Type
7.1. Introduction
7.2. CFTR Modulator Therapies
7.2.1. Potentiators
7.2.2. Correctors
7.2.3. Amplifiers
7.2.4. Combination Therapies
7.3. Symptomatic / Supportive Therapies
7.3.1. Mucolytics
7.3.2. Bronchodilators
7.3.3. Antibiotics
7.3.4. Anti-Inflammatory Drugs
8. Cystic Fibrosis Market, by Route Of Administration
8.1. Introduction
8.2. Inhalation
8.3. Intravenous
8.4. Oral
9. Cystic Fibrosis Market, by End User
9.1. Introduction
9.2. Home Healthcare
9.3. Hospitals
9.4. Specialty Clinics
10. Cystic Fibrosis Market, by Distribution Channel
10.1. Introduction
10.2. Offline Pharmacy
10.2.1. Hospital Pharmacy
10.2.2. Retail Pharmacy
10.3. Online Pharmacy
11. Cystic Fibrosis Market, by Region
11.1. Asia-Pacific
11.2. North America
11.3. Latin America
11.4. Europe
11.5. Middle East
11.6. Africa
12. Cystic Fibrosis Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. Cystic Fibrosis Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Abbott Laboratories
15.2. AbbVie Inc.
15.3. Alaxia SAS
15.4. Anthera Pharmaceuticals, Inc.
15.5. Arcturus Therapeutics Holdings Inc.
15.6. AstraZeneca PLC
15.7. Beyond Air, Inc.
15.8. Boehringer Ingelheim International GmbH
15.9. Chiesi Farmaceutici S.p.A.
15.10. Corbus Pharmaceuticals Holdings, Inc.
15.11. CRISPR Therapeutics AG
15.12. Editas Medicine, Inc.
15.13. Eloxx Pharmaceuticals, Inc.
15.14. F. Hoffmann-La Roche Ltd
15.15. Galapagos NV
15.16. GeneTx Biotherapeutics LLC
15.17. Gilead Sciences, Inc.
15.18. Insmed Incorporated
15.19. Johnson & Johnson Services, Inc.
15.20. Merck & Co., Inc.
15.21. Neovii Biotech GmbH
15.22. Novartis AG
15.23. Novo Nordisk A/S
15.24. Pharmaxis Ltd.
15.25. Proteostasis Therapeutics, Inc.
15.26. PTC Therapeutics, Inc.
15.27. Teva Pharmaceutical Industries Ltd.
15.28. Vertex Pharmaceuticals Incorporated
15.29. Viatris Inc.
15.30. Zambon S.p.A.
List of Figures
FIGURE 1. GLOBAL CYSTIC FIBROSIS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CYSTIC FIBROSIS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CYSTIC FIBROSIS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CYSTIC FIBROSIS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CYSTIC FIBROSIS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CYSTIC FIBROSIS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL CYSTIC FIBROSIS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL CYSTIC FIBROSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CYSTIC FIBROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CFTR MODULATOR THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CFTR MODULATOR THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CFTR MODULATOR THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL POTENTIATORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL POTENTIATORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL POTENTIATORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CORRECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CORRECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CORRECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL AMPLIFIERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL AMPLIFIERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL AMPLIFIERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL SYMPTOMATIC / SUPPORTIVE THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL SYMPTOMATIC / SUPPORTIVE THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL SYMPTOMATIC / SUPPORTIVE THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL MUCOLYTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL MUCOLYTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL MUCOLYTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL BRONCHODILATORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL INHALATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 70. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 76. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 78. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 79. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 80. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 81. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 82. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 83. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 84. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 86. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 87. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 88. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 89. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 90. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 91. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 92. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 94. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 95. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 96. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 97. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 98. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 99. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 100. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 102. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 103. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 104. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 105. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 106. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 107. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 108. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 110. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 111. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 112. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 113. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 114. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 115. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 119. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 120. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 121. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 122. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 123. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 124. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 125. GCC CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. GCC CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 127. GCC CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 128. GCC CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 129. GCC CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 130. GCC CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 131. GCC CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 132. GCC CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 141. BRICS CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. BRICS CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 143. BRICS CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 144. BRICS CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 145. BRICS CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 146. BRICS CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 147. BRICS CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 148. BRICS CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 149. G7 CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 150. G7 CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 151. G7 CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 152. G7 CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 153. G7 CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 154. G7 CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 155. G7 CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 156. G7 CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 157. NATO CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. NATO CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 159. NATO CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 160. NATO CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 161. NATO CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 162. NATO CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 163. NATO CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 164. NATO CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 166. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 167. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 168. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 169. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 170. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 171. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 172. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 173. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 174. CANADA CYSTIC FIBROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 175. CANADA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 176. CANADA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 177. CANADA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 178. CANADA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 179. CANADA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 180. CANADA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 181. CANADA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 182. MEXICO CYSTIC FIBROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 183. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 184. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 185. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 186. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 187. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 188. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 189. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 190. BRAZIL CYSTIC FIBROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 191. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 192. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 193. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 194. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 195. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 196. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 197. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 198. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 199. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 200. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 201. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 202. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 203. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 204. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 205. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 206. GERMANY CYSTIC FIBROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 207. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 208. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 209. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 210. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 211. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 212. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 213. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 214. FRANCE CYSTIC FIBROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 215. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 216. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 217. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 218. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 219. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 220. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 221. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 222. RUSSIA CYSTIC FIBROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 223. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 224. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 225. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 226. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 227. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 228. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 229. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 230. ITALY CYSTIC FIBROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 231. ITALY CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 232. ITALY CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 233. ITALY CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 234. ITALY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 235. ITALY CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. ITALY CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 237. ITALY CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 238. SPAIN CYSTIC FIBROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 239. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 240. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 241. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 242. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 243. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 244. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 245. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 246. CHINA CYSTIC FIBROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 247. CHINA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 248. CHINA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 249. CHINA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 250. CHINA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 251. CHINA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 252. CHINA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 253. CHINA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 254. INDIA CYSTIC FIBROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. INDIA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 256. INDIA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 257. INDIA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 258. INDIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 259. INDIA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 260. INDIA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 261. INDIA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 262. JAPAN CYSTIC FIBROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 263. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 264. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 265. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 266. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 267. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 268. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 269. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 270. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 271. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 272. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 273. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 274. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 275. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 276. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 277. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 278. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 279. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 280. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPIES, 2017-2032 (USD MILLION)
TABLE 281. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC / SUPPORTIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 282. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 283. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 284. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 285. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2017-2032 (USD MILLION)
TABLE 286. GLOBAL CYSTIC FIBROSIS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 287. GLOBAL CYSTIC FIBROSIS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Alaxia SAS
  • Anthera Pharmaceuticals, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • AstraZeneca PLC
  • Beyond Air, Inc.
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici S.p.A.
  • Corbus Pharmaceuticals Holdings, Inc.
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • Eloxx Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Galapagos NV
  • GeneTx Biotherapeutics LLC
  • Gilead Sciences, Inc.
  • Insmed Incorporated
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Neovii Biotech GmbH
  • Novartis AG
  • Novo Nordisk A/S
  • Pharmaxis Ltd.
  • Proteostasis Therapeutics, Inc.
  • PTC Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
  • Zambon S.p.A.

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 7.71 Billion
Forecasted Market Value ( USD ) by 2032 $ 13.61 Billion
Compound Annual Growth Rate9.7%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Cystic Fibrosis Therapeutics Market Report by Drug Class, Drug Molecule Type, Route of Administration, End-User, and Region 2026-2034 - Product Image

Cystic Fibrosis Therapeutics Market Report by Drug Class, Drug Molecule Type, Route of Administration, End-User, and Region 2026-2034

  • Report
  • 139 Pages
  • Global
From
Cystic Fibrosis Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035) - Product Image

Cystic Fibrosis Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

  • Report
  • 400 Pages
  • Global
From
Cystic Fibrosis Therapeutics Market Report by Drugs Type, Route of Administration, Distribution Channel, Countries and Company Analysis 2026-2034 - Product Image

Cystic Fibrosis Therapeutics Market Report by Drugs Type, Route of Administration, Distribution Channel, Countries and Company Analysis 2026-2034

  • Report
  • 200 Pages
  • Global
From
Cystic Fibrosis Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Cystic Fibrosis Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 94 Pages
  • Global
From
Cystic Fibrosis Devices Market - Global Forecast 2026-2032 - Product Image

Cystic Fibrosis Devices Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.